| 000 | 01223 a2200361 4500 | ||
|---|---|---|---|
| 005 | 20250512211323.0 | ||
| 264 | 0 | _c19840107 | |
| 008 | 198401s 0 0 eng d | ||
| 022 | _a0001-5938 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aReyes-Javier, P D | |
| 245 | 0 | 0 |
_aChemotherapy trial with a triple-drug regimen, including once-monthly Rimactane (Rifampicin), in patients with multibacillary types of leprosy. _h[electronic resource] |
| 260 |
_bActa leprologica _c |
||
| 300 |
_a133-41 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aClofazimine _xadverse effects |
| 650 | 0 | 4 |
_aDapsone _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeprosy _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMycobacterium leprae _xisolation & purification |
| 650 | 0 | 4 |
_aRifampin _xtherapeutic use |
| 650 | 0 | 4 |
_aSkin _xmicrobiology |
| 650 | 0 | 4 |
_aSkin Pigmentation _xdrug effects |
| 700 | 1 | _aTantiongco, P R | |
| 773 | 0 |
_tActa leprologica _gvol. 1 _gno. 3 _gp. 133-41 |
|
| 999 |
_c6359716 _d6359716 |
||